



NDA 21-392/S-010

Biovail Technologies Ltd.
On Behalf of Biovail Laboratories International SRL
Attention: Naushad Islam, MS, R.Ph
Director, Regulatory Affairs
700 Route 202/206 North
Bridgewater, NJ 08807

Dear Mr. Islam:

Please refer to your supplemental new drug application dated November 1, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cardizem LA (diltiazem hydrochloride) 120, 180, 240, 300, 360, and 420 mg Extended-Release Tablets.

This "Changes Being Effected" supplemental new drug application provides for revisions to the labeling for Cardizem LA Extended-Release Tablets. Revisions were made to the **PRECAUTIONS, Drug Interactions** subsection of the labeling to add information regarding Buspirone and Quinidine so as to provide adequate information for the safe and effective use of the drug.

We completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the electronic agreed-upon labeling text and with the minor editorial revisions listed below.

Under the **PRECAUTIONS** section, please add hyphens to the following subsections as identified below:

Buspirone, 5.5-fold and C_{max} 4.1-fold, **Benzodiazepines**, (1.5-to 2.5-fold), **Lovastatin**, please change from 3 - 4 times to 3-to4-fold and **Pregnancy**, 60-kg patient

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the enclosed package insert submitted on November 1, 2006. These revisions are terms of the approval of this application.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-392/S-010.**" Approval of this submission by FDA is not required before the labeling is used.

NDA 21-392/S-010

Page 2

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Ms. Denise M. Hinton
Regulatory Project Manager
(301) 796-1090

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosed Labeling

cc: Keller and Heckman LLP
Attention: Mr. John B. Heckman, U.S. Agent
1001 G Street, N.W., Suite 500W
Washington, DC 20001

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Norman Stockbridge
4/27/2007 01:30:48 PM